Homocysteine and heart failure: An overview

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 1, 2009, Pages 15-21

  Vizzardi, Enrico ^a   Bonadei, Ivano ^a   Zanini, Gregoriana ^a   Frattini, Silvia ^a   Fiorina, Claudia ^a   Raddino, Riccardo ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Collagen; Congestive heart failure; Homocysteine; Hyper homocysteinemia; Thrombotic and atherosclerotic vascular disease; Ventricular remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; HOMOCYSTEINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; TROPONIN; VITAMIN B GROUP;

ANGIOGRAPHY; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECHOCARDIOGRAPHY; ENZYME METABOLISM; ENZYME STRUCTURE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FUNCTION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYSTOLIC DYSFUNCTION; VITAMIN SUPPLEMENTATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR DISEASE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; VASCULAR DISEASES; VITAMIN B 12 DEFICIENCY;

EID: 65549141300     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009787259991     Document Type: Review

References (84)

1. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994; 13: S107-112.
2. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J 1999; 20: 447-455.
3. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (Update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
4. Cleland JG, Khand A, Clark A. The heart failure epidemic: Exactly how big is it? Eur Heart J 2001; 22: 623-626.
5. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur Heart J 2004; 25: 1614-1619.
6. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004; 88: 1145-1172.
7. Genetest J, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocysteine levels in men with premature coronary artery disease. JACC 1990; 5: 1114-1119.
8. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268(7): 877-881.
9. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
10. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
11. Vizzardi E, Nodari S, Fiorina C, Metra M, Dei Cas L. Raised homocysteine plasma concentration in patients with heart failure: Clinical significance. Monaldi Arch Chest Dis 2007; 68(2): 96-102.
12. Ubbink JB, Vermaak WJH, Bennett JM , Becker PJ , van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. J Mol Med 1991; 69(12): 527-534.
13. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289: 1251-1257.
14. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 2001; 50: 1466-1471.
15. Frantzen F, Faaren AL, Alfheim I, et al. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-316.
16. Kujitmans LAJ, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101: 2483-2488.
17. Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217-246.
18. Eikelboom JW, Lonn E, Genest J, et al. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
19. Simons, M., Chittenden, T.W.: WO2008048795 (2008).
20. Zettler, M.: US20080175880A1 (2008).
21. Tabibiazar, R., Hytopoulos, E.: WO2008080126 (2008).
22. Douglas, D., Zettler, M.: WO2008046202 (2008).
23. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081.
24. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993; 14(6); 683-693.
25. Tyagi SC. Homocysteine and heart disease: Pathophysiology of extracellular matrix. Clin Exp Hypertens 1999; 21: 181-198.
26. Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, Parker JL. Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem 1998; 181: 107-116.
27. Torres L, Garcia-Trevijano ER, Rodriguez JA, et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: A new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999; 1455: 12-22.
28. Hofmann MA, Lalla E, Lu Y, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-683.
29. Upchurch GR, Welch GN, Freedman JE, Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017.
30. Welch GN, Upchurch GR, Farivar RS, et al. Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF-kappa B dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998; 110(1): 22-31.
31. Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106: 483-491.
32. Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J. Over-expression of cellular glutathione peroxidase rescues homocysteine-induced endothelial dysfunction. Proc Natl Acad Sci USA 2001; 98: 12503-12508.
33. Stuart JM. Plasma total homocysteine: Instigator or indicator of cardiovascular disease? Ann Clin Biochem 2008; 45: 345-348.
34. Joseph J, Joseph L, Shekhawat N, et al. Hyperhomocysteinemia leads to pathologic ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003; 285: H679-H686.
35. Joseph J, Washington A, Joseph L, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling and dysfunction in hypertensive rats. Am J Physiol Heart Circ Physiol 2002; 283: H2567-H2574.
36. Sulochana D, Richard HK, Lija J, Nawal SS, Russell BM, Jacob J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006; 15: 75-82.
37. Joseph J, Washington A, Joseph L, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling and dysfunction in hypertensive rats. Am J Physiol 2002; 283: H2567-H2574.
38. Joseph J, Joseph L, Shekhawat N, et al. Hyperhomocysteinemia leads to pathologic ventricular hypertrophy in normotensive rats. Am J Physiol 2003; 285(2): H679-686.
39. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and the rennin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
40. Bing OH, Brooks WW, Robinson KG, et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 1995; 27(1): 383-396.
41. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: A role for interstitial fibrosis. Mol Cell Biochem 1995; 147: 29-34.
42. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: Interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41: 532-543.
43. Moshal KS, Tipparaju SM, Vacek TP, et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008; 295(2): H890-H897.
44. Moshal KS, Metreveli N, Frank I, Tyagi SC. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 2008; 6(2): 84-92.
45. Moshal KS, Camel CK, Kartha GK, et al. Cardiac dyssynchronization and arrhythmia in hyperhomocysteinemia. Curr Neurovasc Res 2007; 4(4): 289-294.
46. Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 2006; 98(5): 1150-1162.
47. Jacob J, Richard HK, Sulochana D. Protective role of mast cells in homocysteine-induced cardiac remodelling. Am J Physiol Heart Circ Physiol 2005; 288: H2541-H2545.
48. Richard HK, Richard O, Jacob J, Russell BM, Martin H-J, Marjan B. Acute dilatory and negative inotropic effects on homocysteine are inhibited by an adenosine blocker. Clin Exp Pharmac Physiol 2006; 33: 340-344.
49. Kennedy RH, Owings R, Shekhawat N, Joseph J. Acute negative inotropic effects of homocysteine are mediated via the endothelium. Am J Physiol 2004; 287: H812-H817.
50. Upchurch GR, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017.
51. Stühlinger MC, Tsao PS, Her J-H, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-2575.
52. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98: 5-7.
53. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
54. Ungvari Z, Csiszar A, Bagi Z, Koller A. Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: Morphological and functional evidence for increased peroxynitrite formation. Am J Pathol 2002; 161: 145-153.
55. Herrmann W, Herrmann M, Joseph J, Tyagi SC. Homocysteine, brain natriuretic peptide and chronic heart failure: A critical review. Clin Chem Lab Med 2007; 45(12): 1633-1644.
56. Herrmann M, Taban-Shoma O, Hubner U, et al. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Clin Chem 2007; 53(4): 773-780.
57. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002; 15: 157-163.
58. Al Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MI. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1217-1222.
59. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
60. Lentz SR. Homocysteine and vascular dysfunction. Life Sci 1997; 61: 1205-1215.
61. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
62. Blacher J, Demuth K, Guerin AP, et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999; 12: 248-255.
63. Wocial B, Berent H, Kostrubiec M, Kuczynska K, Kuch-Wocial A, Nieweglowska N. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press 2002; 11: 201-205.
64. Cooke GE, Eaton GM, Whitby G, et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) atients. J Am Coll Cardiol 2000; 36: 509-516.
65. Ueland PM, Nygard O, Vollset SE, Refsum H. The Hordaland Homocysteine Studies. Lipids 2001; 36: S33-S39.
66. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
67. Schofield RS, Wessel TR, Walker TC, Cleeton TS, Hill JA, Aranda Jr JM. Hyperhomocysteinemia in patients with heart failure referred for cardiac transplantation: preliminary observations. Clin Cardiol 2003; 26: 407-410.
68. Ramachandran SV, Alexa B, Ralph BD, et al. Failure in adults without prior myocardial infarction plasma homocysteine and risk for congestive heart. JAMA 2003; 289: 1251-1257.
69. Sundstrom J, Sullivan L, Selhub J, et al. Relations of plasma homocysteine to left ventricular structure and function: The Framingham Heart Study. Eur Heart J 2004; 25: 523-530.
70. Nasir K, Tsai M, Rosen BD, et al. Elevated homocysteine is associated with reduced regional left ventricular function the multiethnic study of atherosclerosis. Circulation 2007; 115: 180-187.
71. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
72. Retterstol L, Paus B, Bohn M, et al. Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: A 10-year follow-up study. J Intern Med 2003; 253: 284-292.
73. Rossi GP, Seccia TM, Pessina AC. Homocysteine, left ventricular dysfunction and coronary artery disease: Is there a link? Clin Chem Lab Med 2007; 45(12): 1645-1651.
74. Cesari M, Zanchetta M, Burlina A, et al. Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 2005; 25: 115-121.
75. Herrmann M, Kindermann I, Muller S, et al. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem 2005; 51: 1512-1515.
76. Naruszewicz M, Jankowska EA, Zymlinski R, et al. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance-pilot study. Atherosclerosis 2007; 194(2): 408-414.
77. May HT, Alharethi R, Anderson JL, et al. Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology 2007; 107(3): 178-184.
78. Guéant-Rodriguez RM, Juillière Y, Nippert M, et al. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. J Thromb Haemost 2007; 5(6): 1209-1216.
79. Gorelik O, Moznino-Sarafian D, Feder I, et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 2003; 99:177-181.
80. Herzlich BC, Lichstein E, Schulhoff N, et al. Relationship among homocyst(e)ine, vitamin B-12 and cardiac disease in the elderly: Association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. J Nutr 1996; 126: 1249S-1253S.
81. Herrmann M, Muller S, Kindermann I, et al. Plasma B vitamins and their relation to the severity of chronic heart failure. Am J Clin Nutr 2007; 85: 117-123.
82. Witte KK, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005; 26: 2238-2244.
83. Devia S, Kennedye RH, Joseph L, Shekhawatd NS, Melchertc RB, Joseph J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006; 15: 75- 82.
84. Bokhari SW, Bokhari ZW, Zell JA, Lee DW, Faxon DP. Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients. Coron Artery Dis 2005; 16: 153-161.